Clinical Trial Update: TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) [Phase 2]

View source ↗

Summary

A Phase 2 trial (TASK-02) evaluating transarterial chemoembolization plus sintilimab and a bevacizumab biosimilar in advanced hepatocellular carcinoma has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED